{"denomUnitsSelected":"Participants","description":"Plasma and CSF PK levels of TORC1/2 inhibitor MLN0128 obtained before and after bevacizumab administration will be evaluated and summarized. The ration of plasma to CSF PK levels will also be summarized.","reportingStatus":"NOT_POSTED","timeFrame":"2-3 hours post-dose day 15 of course 1 and day 1 of course 2","title":"Cerebrospinal Fluid (CSF) Penetration of TORC1/2 Inhibitor MLN0128, Evaluated Using Plasma and CSF Pharmacokinetic (PK) Parameters of MLN0128","type":"OTHER_PRE_SPECIFIED"}